Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
- Conditions
- Advanced Solid TumorBreast Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Treadwell Therapeutics, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT05251714
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START - Mountain Region, West Valley City, Utah, United States
Study of INCB123667 in Subjects With Advanced Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 604
- Registration Number
- NCT05238922
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope-Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Biological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab Emtansine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Conditions
- HER2-positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05230810
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Conditions
- Head and Neck CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05226871
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, China
🇺🇦Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, Dnipro, Ukraine
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- Conditions
- PIK3CA MutationSolid Tumor, AdultHER2-negative Breast CancerBreast CancerMetastatic Breast CancerAdvanced Breast CancerUnresectable Solid TumorEndometrial Cancer
- Interventions
- Drug: PF-07220060 100mgDrug: PF-07220060 300 mg
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 890
- Registration Number
- NCT05216432
- Locations
- 🇺🇸
HealthONE, Denver, Colorado, United States
🇪🇸START Barcelona, Barcelona, Catalonia, Spain
🇪🇸Institut Catala D'Oncologia - Badalona (ICO Badalona), Barcelona, Spain
Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 20
- Registration Number
- NCT05191914
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
- Conditions
- Advanced Breast CancerBreast TumorMetastatic Breast CancerBreast CarcinomaCancer of the BreastBreast CancerMalignant Tumor of BreastCancer of Breast
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- Nuvation Bio Inc.
- Registration Number
- NCT05191004
- Locations
- 🇺🇸
Pennsylvania Cancer Specialists and Research Institute, Gettysburg, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Compassionate Cancer Care Research Inc., Fountain Valley, California, United States
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 120
- Registration Number
- NCT05181033
- Locations
- 🇸🇬
Nationa University Hospital, Singapore, Singapore
Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT05176080
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.